RENOUNCE.

We’ve been following the highs and lows of the olaratumab saga for a while now. As a reminder, in phase 2 it was reported to nearly double median survival for patients with unresectable or metastatic soft tissue sarcoma when added to the standard doxorubicin. This was followed by abstract reporting last year at ASCO that survival was actually significantly worse with olaratumab on a similarly-designed phase 3 follow-on ANNOUNCE trial. Now that we’ve had time to recover from the whiplash, the final pub is out. At a median follow-up of 31 months for 509 patients, median survival was 20 months across the board. A little over half of enrollees stained positive of PDGFRɑ (the target of olaratumab), but it had no correlation with response or survival. TBL: It’s back to the drawing board for systemic treatment of soft tissue sarcoma. | Tap, JAMA 2020